ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Advances in the Research of Targeting B Cells for the Treatment of Systemic Lupus Erythematosus Xiaonisha
July 25, 2025Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease. The direct cause of SLE pathogenesis lies in the immune imbalance resulting from excessive B-cell activation. -
UCB and Biogen's lupus drug falls short at Phase 2b
pharmafile
October 25, 2018The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment... -
STELARA Shows Positive Results In Treatment of Systemic Lupus Erythematosus
americanpharmaceuticacreview
November 07, 2017Based on the results of the Phase 2 study results, Janssen plans to advance STELARA into a Phase 3 SLE development program in 2018. -
GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus
pharmaceufical-technology
September 30, 2017Indicated for patients who are inadequate responders to existing therapies, Benlysta is approved for use as an add-on therapy in autoantibody-positive SLE patients.
Pharma Sources Insight July 2025
